Myeloma Today Spring 2012 Volume 9 Issue 1

Dear Reader

A Message from the President

Scientific & Clinical

  • "Best of ASH 2011 Recap: What Patients Need to Know" by Dr. Brian Durie
  • "2012 IMF Research Grants" by Dr. Robert Kyle
  • "Relapsed Multiple Myeloma After Therapy with IMiDs and Bortezomib" -Myeloma Today in Conversation with Dr. Shaji Kumar

Supportive Care

  • IMF Hotline Coordinators Answer Your Questions - My doctor has talked to me about Velcade infusions as part of my myeloma therapy. I have read that the drug is now approved for subcutaneous administration. How does this compare to receiving Velcade intravenously?


News & Notes

  • IMF Welcomes New Members to Its Board of Directors
  • Prof. Dr. Mario Boccadoro
  • Andy Kuzneski, III
  • Prof. Dr. Heinz Ludwig
  • Get Your Myeloma Today Online.
  • IMF Staff Updates
  • Aimee Martin, Grassroots Liaison
  • Chelsea Proctor, Executive Assistant

Nurse Leadership Board

  •  Survivorship Care Plan - Renal Complications in Multiple Myeloma and Related Disorders

Education and Awareness

  • Spotlight on Advocacy
  • New jersey becomes 15th state to pass oral chemotherapy access bill
  • IMF's support group leader makes huge impact at press conference in Delaware
  • Capitol Hill Bulletin
  • How to contact the IMF Advocacy Team
  •  "2012 Boca Raton IMF Patient & Family Seminar" by Tom Callaghan

International Affiliates

  • Updates from Asia
  • Training Doctors from China
  • IMF's Asian Myeloma Network Meets at ASH
  • Landmark Agreement signed in Shenzhen, China
  • Second Singapore National Patient Forum

Member Events

  • Fundraisers are supporting research through the Brian D. Novis Research Grant Program
  • Jack Aiello's Poker Bash
  • Matt Jacob's Letter Campaign
  • Upcoming Member Events

Investing in the Future

  • Myeloma 200 - Closer to a Cure

2012 IMF Calendar of Events


Letters to the IMF

Click here to download Myeloma Today

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.